对多发性硬化症的组合疗法进行更新:我们现在在哪里?
Per Soelberg Sorensen1,2, Melinda Magyari1,2,3, Finn Sellebjerg1,2
1Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark.
Expert review of neurotherapeutics
|December 7, 2023
概括
使用现有的平台治疗或重新定位的药物治疗多发性硬化症 (MS) 的组合疗法已经显示出有限的成功. 未来的研究可能将重点放在将新型神经保护剂与强效抗炎药物结合起来,以改善MS治疗.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 组合疗法可以增强治疗效果,当单个药物是次优的.
- 这种方法已在治疗艾滋病毒,癌症和类风湿性关节炎等自身免疫性疾病方面表现出有效性.
研究的目的:
- 审查多发性硬化症 (MS) 的组合或附加疗法的临床试验.
- 评估治疗疾病活动,不良反应,复发和MS中的复髓化.
主要方法:
- 随机,安慰剂控制或比较双盲/调查者盲目的临床试验的系统性文献综述.
- 排除开放标签试验. 没有开放标签试验.
主要成果:
- 结合使用贝塔干扰素或glatiramer酸盐没有显示任何额外的益处.
- 大多数使用重定向药物的附加疗法是无效的,甲基普雷尼索隆的耐受性较低.
- 一些神经保护/复髓化组合疗法产生了有希望的结果,正在等待III期试验.
结论:
- 目前针对多发性硬化症的抗炎疗法的组合治疗通常令人失望.
- 未来的策略可能涉及将新型神经保护剂/复髓化药物与MS的先进抗炎疗法结合起来.
- 需要进一步的研究来确定多发性硬化症的有效组合疗法.
相关概念视频
Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Electroconvulsive Therapy
44
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
44


